CN117958423A

CN117958423A - Freeze-dried powder composition, preparation method thereof and chewable tablet

Info

Publication number: CN117958423A
Application number: CN202410281723.7A
Authority: CN
Inventors: 束红辉; 李克峰; 邓木俊
Original assignee: Danyang Xingda Optical Devices Co ltd
Current assignee: Danyang Xingda Optical Devices Co ltd
Priority date: 2024-03-12
Filing date: 2024-03-12
Publication date: 2024-05-03

Abstract

The invention provides a freeze-dried powder composition for eye protection and health care, a preparation method thereof and chewable tablets for eye protection and health care. The lyophilized powder composition is prepared from a dispersion comprising lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt, chocolate, vitamin C, zinc oxide, cupric citrate, emulsifying agent, co-emulsifying agent, excipient, and liquid glyceride by freeze drying. The freeze-dried powder composition of the present invention has improved storage stability, bioavailability and eyesight protection effects.

Description

Freeze-dried powder composition, preparation method thereof and chewable tablet

Technical Field

The invention relates to the field of dietary supplements for vision care, in particular to a freeze-dried powder composition for vision care, a method for preparing the freeze-dried powder composition and chewable tablets prepared by using the freeze-dried powder composition. The invention also relates to application of the chewable tablet in protecting vision, relieving visual fatigue, promoting eye health and the like.

Background

The physical nature of light is high frequency electromagnetic waves. The phosphor screen emits an electron-bright light containing blue light having a wavelength between 400nm and 500nm, near ultraviolet light. The shorter the wavelength, the higher the energy, which is easy to penetrate the lens, generating free radicals, resulting in clouding of the lens; when blue light reaches the retina, photochemical damage is generated to the photoreceptor cells, the retina contains 1.3 hundred million rod cells and 700 ten thousand cone cells, and accumulated damage can lead to gradual apoptosis of the photoreceptor cells, unlike myopia caused by blue light. Lens accommodation dysfunction ultimately leads to blurred vision and reduced resolution of the macula (consisting entirely of dense cones), which must be brought closer to the eye for clarity.

The statistics show that the number of myopia in China is up to about 4 hundred million, and the number of teenagers is about 2.7 hundred million. The incidence rate of myopia of students in middle and primary schools is more than 50%, and the rate of poor eyesight detection such as astigmatism, blur, presbyopia and the like is increased, so that the eye health is seriously affected. On the other hand, vision deterioration such as myopia and astigmatism is also caused by aging of the organism from the scientific mechanism. Aging refers to a comprehensive degeneration of the body, which is caused by the gradual and slow deterioration of the functions of various tissues and organs of the body and the weakening of many immune functions of the body, due to the long-term impact and damage of the body cell population by the above factors in the life cycle of the human.

In addition to the effect of the external environment on vision formation, the supply of nutrients required during eye development is critical to the healthy normal development of eye tissue. The eyes begin to develop the third week of pregnancy. The development of the fetus is closely related to the nutritional status of the pregnant woman, and the development of the fetal eyes depends on the concentration of carotenoids such as lutein in the pregnant woman. Lutein can prevent myopia, and the lack of nutrient substances such as lutein is one of the causes that myopia can inherit, and a fetus cannot obtain enough lutein from a mother body in the development process, so that eyes excessively regulate light rays to induce myopia. The breast milk contains lutein, and the lutein required for eye development can be obtained after the birth of the fetus by breast feeding. Myopia, hyperopia and astigmatism of children are all manifestations of vision hypoevolutism, and amblyopia can be formed if nutrients required by eye development are not timely supplemented, so that difficulty in vision recovery is increased.

After entering the eye, the light passes through the cornea, aqueous humor, lens, vitreous body, and reaches the retina, where there are two types of photoreceptor cells: rod-shaped cells and cone-shaped cells; the rod cells are responsible for low-light vision, and the cone cells are responsible for processing colors and details; when exposed to light, a series of chemical reactions occur and activate rhodopsin in the optic nerve, thereby producing an electronic pulse signal. As described above, when high energy blue light is injected into the eye, a large amount of radicals are generated in the lens and retina.

The research in the period of life science parents discovers that the oxidative damage of active oxygen and free radicals to the cell tissues in the human body is the main cause of more than 100 diseases such as aging, arteriosclerosis, hypertension, thrombus, coronary heart disease and the like, cerebral infarction, cancer formation and metastasis, pancreatitis, diabetes, nephropathy, liver diseases, gastrointestinal ulcers, vision deterioration, macular degeneration, cataract, hyperthyroidism, skin aging, alzheimer disease, epilepsy and the like. Every cell of the human body is challenged with 1-1 ten thousand times per day by free radicals. According to mutation accumulation theory: lesions and senescence started from each single cell, senescence occurred at each breath; when cells and tissues are exposed to active oxygen or free radicals, oxidative stress can cause various oxidative reactions of cellular components such as lipids, glucose, proteins, DNA, RNA, etc., and induce oxidative damage such as denaturation, crosslinking, rupture, etc., thereby causing destruction of cellular structures and functions and damage of tissues and organs.

To maintain normal operation and health of the body, it resists damage from various reactive oxygen species and free radicals: 1. various antioxidants exist in the body, and can inhibit the generation of various active oxygen and free radicals; 2. capturing and combining the formed active oxygen and free radicals to make the active oxygen and free radicals a non-aggressive stabilizer; 3. repairing or regenerating cells damaged by free radicals; 4. improving the defensive ability, and under certain conditions, the subsequent support of various antioxidant enzymes is just like the backup strength. Although various antioxidants protect against active oxygen in aerobic organisms, such insufficient protection effects, such as ultraviolet light and high-energy blue light irradiation, cause eye diseases, visual deterioration, and the like. Mildewed foods, smoking, strenuous exercise, mental stress, etc., the balance between active oxygen and free radical production and elimination is disrupted, oxidative damage occurs, which also results in decreased vision and impaired normal function of the eye.

In order to maintain the balance and inhibit oxidative damage, dietary supplements are an effective and common practice. Lutein is a common active ingredient in dietary supplements. Lutein is a main carotenoid in human macula and retina, widely exists in plants such as marigold, pumpkin and cabbage, and has biological activities of preventing brain aging, protecting vision, relieving asthenopia, promoting eye health and the like. Lutein mainly protects retina through two ways, one is to inactivate singlet oxygen and capture active oxygen free radical by utilizing the reducibility of the lutein, so as to achieve the effect of protecting photosensitive cells; another is to use its filtering effect on blue light to prevent it from reaching the underlying structure of the retina, thereby reducing the risk of photo-induced oxidative damage.

In addition to lutein, it has been clinically proven that some vitamins (e.g., vitamin D, E, A or C) are important components for maintaining normal eye function, e.g., vitamin C is the main nutritional component of the eye lens, and insufficient intake is prone to lens clouding cataract, keratitis, and iris bleeding. Vitamins can reduce the damage of light and oxygen to the lens of the eye, thereby delaying the occurrence of cataract. In addition, many vitamins are antioxidants that help the eye from free radical threats.

However, both lutein and vitamins are susceptible to high temperature, oxygen, light and extreme pH, and are susceptible to oxidation, instability problems, and product quality, thus limiting their use in dietary supplements or nutritional supplements. Furthermore, several studies have shown that lutein has a lower bioavailability than other carotenoids, which is related to its molecular structure and chemical nature. The molecular structure of lutein contains oxygen-containing functional groups and non-conjugated double bonds, and the structures can reduce the stability and solubility of lutein in intestinal tracts, so that the digestion, absorption and utilization of lutein are affected.

Certain fat-soluble vitamins (e.g., natural vitamin E) also have low bioavailability and in vivo stability in vivo, affecting their absorption availability.

Thus, there is still a need to further improve the storage stability and bioavailability problems of lutein and vitamins as active ingredients, which limit the use of lutein and vitamins in dietary supplements or functional supplements.

Summary of The Invention

The invention aims to provide an improved lutein and vitamin synergistic combination functional composition which has the functions of protecting eyesight, relieving visual fatigue, promoting eye health and the like, and also has improved stability and bioavailability, which greatly promotes the application of lutein and vitamins in dietary supplements or functional supplements.

The inventors have unexpectedly found that the preparation of lyophilized powder from a monoester sodium salt reaction product (e.g., lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt) produced by reacting natural vitamin E with She Huangsuan together with specific excipients can significantly improve the stability and bioavailability of vitamin E and She Huangsuan, and also enhance the synergistic effect of vitamin E and She Huangsuan on the retina, thereby alleviating asthenopia and promoting eye health. In addition, by adding blueberry powder into the freeze-dried powder formula, a cationic complex of carboxylic acid anions-anthocyanin can be formed between lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt and main active ingredients-blueberry anthocyanin in the blueberry powder, so that the stability of vision protection active ingredients is further improved, the effectiveness and bioavailability of the freeze-dried powder composition are improved, and the application of the freeze-dried powder composition in dietary supplements and functional supplements is expanded.

Specifically, the present invention provides:

1. A freeze-dried powder composition for eye protection and health care is prepared by freeze-drying a dispersion liquid, wherein the dispersion liquid comprises lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt represented by a formula I, chocolate, vitamin C, zinc oxide, cupric citrate, emulsifying agent, coemulsifier, excipient and liquid glyceride,

Wherein R is a residue of succinic acid monosodium salt after removal of one carboxylic acid group,

R' is the residue of a tocopherol-succinic acid monoester after removal of one carboxylic acid group.

Preferably, the vitamin C is ascorbic acid or sodium ascorbate, and the starting materials of the lyophilized powder composition comprise: lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt 0.1-0.5 weight parts, chocolate powder 1-5 weight parts, vitamin C1-5 weight parts, zinc oxide 0.1-0.9 weight parts, cupric citrate 0.05-0.5 weight parts, emulsifying agent 1-5 weight parts, co-emulsifying agent 3-15 weight parts, excipient 5-15 weight parts, and liquid glyceride 65-86 weight parts.

Preferably, the raw material components of the lyophilized powder composition further comprise 5-15 parts by weight of blueberry powder, and the blueberry powder contains 20 to 40% by weight of blueberry anthocyanin.

Preferably, the emulsifier is selected from at least one of sorbitan sesquioleate, polysorbate, hydrogenated lecithin, hydrogenated castor oil polyoxyethylene ether-40, vitamin E polyethylene glycol succinate, span-85, and tween-20;

preferably, the co-emulsifier is selected from at least one of polyethylene glycol-400, 1, 2-propanediol and glycerol,

Preferably, the excipient is selected from at least one of inositol, mannitol, lactose, sucrose, maltose, trehalose.

Preferably, the liquid glyceride is selected from at least one of glyceryl triacetate, glyceryl tricaprate and glyceryl caprylate.

Preferably, the water content of the dispersion is controlled to be less than 0.5 wt.%.

2. A method of preparing a lyophilized powder composition for eye care comprising the steps of:

S1, placing chopped chocolate in a container with water being wiped, then placing the container in hot water with the temperature of more than 60 ℃, adding liquid glyceride for stirring, and filtering to obtain a filtered chocolate dispersion;

s2, adding an emulsifying agent, a co-emulsifying agent, zinc oxide and cupric citrate into the filtered chocolate dispersion liquid, adding into a mixer, stirring and uniformly mixing for 30-120 minutes, placing into a water bath kettle for 30-90 minutes after uniform stirring, and performing heat treatment at 50-70 ℃ to obtain a first dispersion liquid;

S3, cooling the first dispersion liquid to room temperature, adding lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt represented by the formula I, vitamin C and excipient, uniformly stirring to obtain a second dispersion liquid,

R' is the residue of a tocopherol-succinic acid monoester after removal of one carboxylic acid group;

S4, placing the second dispersion liquid in a vacuum freeze dryer for vacuum freeze drying for 2-5 hours, wherein the vacuum pressure is 150-300Pa, and the temperature is-20-40 ℃ to obtain a block;

and S5, ball milling the block obtained in the step S4, and then conveying the ball-milled powder into a sieving machine for sieving, thereby obtaining the freeze-dried powder composition.

Preferably, step S3 further comprises adding blueberry powder to the first dispersion, and the blueberry powder contains 20 to 40 wt% blueberry anthocyanin.

Preferably, the vitamin C is ascorbic acid or sodium ascorbate, and the raw material components of the freeze-dried powder composition are as follows: lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt 0.1-0.5 weight parts, chocolate powder 1-5 weight parts, vitamin C1-5 weight parts, zinc oxide 0.1-0.9 weight parts, cupric citrate 0.05-0.5 weight parts, emulsifying agent 1-5 weight parts, co-emulsifying agent 3-15 weight parts, excipient 5-15 weight parts, and liquid glyceride 65-86 weight parts.

3. A chewable tablet for eye care and health care, wherein the chewable tablet is prepared by tabletting the following raw materials: the lyophilized powder composition for eye protection according to any one of claims 1 to 6, which comprises 30 to 50 wt%, xylitol 1 to 35 wt%, maltitol 1 to 35 wt%, maltodextrin 1 to 10 wt%, microcrystalline cellulose 1 to 15 wt%, polyvinylpyrrolidone 1 to 5 wt%, magnesium stearate 0.1 to 0.5 wt%, and the total amount is 100 wt%.

The invention has the beneficial effects that:

(1) The vitamin E which lacks stability and has low bioavailability is reacted with lutein to generate lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt shown in the formula I. After esterification of vitamin E and lutein, stability is increased. In addition, the bioavailability and stability of lutein and tocopherol obtained by decomposing lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt are higher than those of free lutein and tocopherol, so that the retina function can be obviously improved, and the eyesight can be improved. The compound of the invention is decomposed into lutein and tocopherol again in vivo to play a role, and solves the problems of low activity, too fast metabolism and low bioavailability of lutein and tocopherol in vivo.

(2) The freeze-dried powder formula of the invention prepares the active ingredients such as chocolate powder, blueberry powder, lutein, tocopherol and the like into dispersion liquid in the form of small particles or uniformly dispersed molecules by means of the emulsifier and the auxiliary emulsifier, so that the small-size and even uniformly dispersed state of the active ingredients can be obtained, and then the small-size and even dispersed state of the active ingredients are kept by freeze drying, so that the active ingredients can be better absorbed by human bodies, and the taste is also more excellent.

(3) As described above, in the preparation process of the present invention, blueberry powder may be further added to a second dispersion liquid comprising flavin succinic acid-tocopherol monoester-succinic acid monoester sodium salt, vitamin C and an excipient, and in the state of this dispersion liquid, since lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt has a carboxylate anionic group at one end, it can form a complex with the cation of blueberry phyllotoxin in blueberry powder, further improving the stability and availability of active ingredient, and animal experiments prove that the freeze-dried powder composition of the present invention has better eye protection effect compared to the physical mixture of active ingredient, and can be further prepared into chewable tablets with good compliance.

(4) The invention can also combine the freeze-dried powder composition with auxiliary materials to prepare chewable tablets, solves the problem of uneven mixing of raw materials of the existing vitamin chewable tablets, and improves the absorbability and bioavailability of the tablets.

Detailed Description

In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It will be understood, however, that the invention may be practiced without these specific details.

In one aspect, the present invention provides a lyophilized powder composition for eye protection and health care, which is prepared by freeze-drying a dispersion comprising lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt represented by formula I, chocolate, vitamin C, zinc oxide, cupric citrate, emulsifying agent, co-emulsifying agent, excipient and liquid glyceride,

According to an embodiment of the present invention, the raw materials used for preparing the lyophilized powder composition comprise the following components: lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt represented by formula I, chocolate, vitamin C, zinc oxide, cupric citrate, emulsifying agent, coemulsifier, excipient, liquid glyceride and the like. The above components and their actions are described in detail below.

Lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt

Lutein succinic acid-tocopheryl monoester-succinic acid monoester sodium salt is prepared by esterification of one hydroxyl group of lutein with natural vitamin E (preferably DL-alpha-tocopherol) succinic acid monoester, and then forming the other hydroxyl group into succinic acid sodium salt. The structure of the lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt is shown as formula I, wherein the lutein succinic acid-tocopherol monoester is formed at one end of a lutein mother nucleus, and carboxylate anionic groups are arranged at one end of the lutein succinic acid-tocopherol monoester sodium salt. By forming single ester compound salt of the lutein and the vitamin E, the preservation stability of the vitamin E and the lutein is improved, and the problem that the vitamin E and the lutein are easy to oxidize is solved. Can also improve the stability and bioavailability in vivo, so that vitamin E and lutein can better enter blood to play a synergistic effect, strengthen the function of retina and protect eye health. Free lutein and vitamin E can lose a great part of the lutein and vitamin E due to decomposition or excretion in the process of entering blood circulation, however, lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt has higher in-vivo stability, avoids the loss before entering blood circulation, and promotes more active ingredients such as lutein, vitamin E and the like to enter blood to play a synergistic effect on retina.

Chocolate

Chocolate can be used as flavoring agent in lyophilized powder composition, and can also be used together with lutein, vitamin E, blueberry, etc. for protecting eye health and relieving eye diseases. While not being limited by theory, it is believed that chocolate produces exciting dopamine which has a pronounced inhibitory effect on the ocular axis. A very high proportion of teenagers are caused by too fast an increase in the ocular axis.

In addition, chocolate is present in a small size dispersed form in the lyophilized powder composition, is easily absorbed, and functions better.

Vitamin C

Vitamin C is one of the active ingredients in the freeze-dried powder composition, can delay the aging of eyes, and can remove part of active oxidized substances, play a role in eliminating free radicals of eyes and prevent the aging of eyes to a certain extent because the vitamin C has a certain antioxidation function. Vitamin C can also improve local blood circulation, thereby relieving asthenopia and reducing risk of vision deterioration. Vitamin C can also promote the utilization of vitamin A by the organism, enhance the stability of vitamin A, and maintain normal vision, so that vitamin C can indirectly play a role in maintaining the vision of eyes.

Vitamin C can exert a protective effect on eyes and promote eye health in cooperation with lutein and tocopherol. In addition, by including vitamin C in the lyophilized powder, the stability thereof can be improved, and oxidation thereof can be prevented without adding an antioxidant.

Preferred vitamin C is sodium ascorbate or ascorbic acid.

Zinc oxide and cupric citrate

The freeze-dried powder composition of the present invention further contains trace elements such as zinc and copper which are beneficial to eye health. Zinc is added to the composition in the form of zinc oxide and copper is added in the form of copper citrate. Zinc is very important for the health of the retina and the function of vitamin a. Zinc was a supplement previously used in a study that showed it to be significantly better than placebo in delaying changes in macular degeneration. Zinc is also considered an important cofactor for a variety of metalloenzymes, the most important of which is superoxide dismutase, which scavenges the strong oxidant, superoxide. There are two types of SOD in mammalian cells. One type contains copper and zinc, located in the cytoplasmic and periplasmic space of the mitochondria. The other type contains manganese and is located in the mitochondrial matrix. Mitochondria are the sites of high metabolic activity and rapid oxidative processes in the retina. These subtypes of SOD and zinc are also associated with cataracts, since both superoxide dismutase activity and zinc are significantly lower in cataract patients than in non-cataract patients. Zinc is also involved in enzymes associated with vitamin a metabolism, regulating esterification levels.

By adding zinc in the form of zinc oxide, it is most easily dissolved, causes minimal irritation, and works most rapidly and fully.

Copper is another important cofactor for metalloenzymes and is also the second essential cofactor for superoxide dismutase. Studies have shown that copper levels in humans over 70 years of age are reduced, while the copper levels in cataractous lenses are essentially zero.

If copper is reduced, superoxide dismutase function is reduced, thereby impeding the important lens protection mechanism. Copper also prevents the toxicity of zinc, which can hinder the absorption of zinc, thus reducing bioavailability.

Thus, the formulation of the lyophilized powder composition of the present invention also adds copper in salt form.

Emulsifying agent and co-emulsifying agent

In order to improve the dispersibility of insoluble components (such as chocolate, lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt, blueberry powder and the like) in the freeze-dried powder composition, a proper amount of emulsifying agent and auxiliary emulsifying agent are required to be added.

Examples of the emulsifier suitable for the present invention include at least one of sorbitan sesquioleate, polysorbate, hydrogenated lecithin, hydrogenated castor oil polyoxyethylene ether-40, vitamin E polyethylene glycol succinate, span-85 and tween-20.

Preferred emulsifiers are hydrogenated lecithin and vitamin E polyethylene glycol succinate (TPGS). TPGS is a water-soluble derivative of natural vitamin E. It is a surfactant containing a lipophilic group and a hydrophilic group in the molecule. Vitamin E TPGS is a pale yellow waxy solid, almost odorless, soluble in water, and soluble in most polar organic solvents such as ethanol. Vitamin E deficiency, originally developed for the treatment of malabsorption patients, is now used as an effective enhancer in formulations to increase the bioavailability of lipophilic and poorly soluble substances. Vitamin E TPGS has unique properties and has long-lasting safety in medicine, cosmetics, food and animal feed.

The co-emulsifier may be selected from at least one of polyethylene glycol-400, 1, 2-propanediol, and glycerol.

Excipient

The excipient may be at least one selected from inositol, mannitol, lactose, sucrose, maltose, and trehalose. The excipient mainly maintains the loose dispersion state of the powder during freeze-drying, so that the solubility is improved, and the freeze-dried powder has better appearance.

Preferred excipients are mannitol and maltose. Mannitol, also known as mannitol, is prepared from starch sugar or sucrose as raw material, and is a common humectant for medicines and cosmetics. The invention also serves as a main excipient of the freeze-dried powder.

Liquid glyceride

The liquid glyceride serves as a dispersion medium during the preparation of the lyophilized powder composition and is an edible dispersion medium.

Preferably, the liquid glyceride is selected from at least one of glyceryl triacetate, glyceryl tricaprate and glyceryl caprylate, most preferably glyceryl caprylate.

Preparation of lyophilized powder composition

The invention also provides a method for preparing the freeze-dried powder composition for eye protection and health care, which comprises the following steps:

s1-placing the chopped chocolate in a container of water which has been wiped off, then placing the container in hot water above 60 ℃, adding liquid glycerides, stirring, and filtering to obtain a filtered chocolate dispersion. Preferably, the temperature of the hot water is around 60 ℃. The chopped chocolate is placed in a container of water that has been wiped off, and then the container is placed in hot water. When the chocolate becomes liquid, a long handle spoon is used for stirring clockwise

S2, adding an emulsifying agent, a coemulsifier, an excipient, zinc oxide and cupric citrate into the filtered chocolate dispersion liquid, adding into a mixer, stirring and mixing for 30-120 minutes, placing into a water bath kettle for 30-90 minutes after stirring uniformly, and performing heat treatment at 50-70 ℃ to obtain a first dispersion liquid;

R' is a salt of the residue of a dl-alpha-tocopherol-succinic acid monoester after removal of one carboxylic acid group;

s4, placing the second dispersion liquid in a vacuum freeze dryer for vacuum freeze drying for 2-5 hours, wherein the vacuum pressure is 150-300Pa, and the temperature is-20 to-40 ℃ to obtain a block;

Preferably, step S3 further comprises adding blueberry powder to the second dispersion, and the blueberry powder contains 20 to 40 wt% blueberry anthocyanin.

As raw materials for preparing the dispersion liquid, the mixture ratio is preferably 5-15 parts by weight of lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt, 1-5 parts by weight of chocolate powder, 10-20 parts by weight of vitamin C, 0.2-2 parts by weight of zinc oxide, 0.05-1.5 parts by weight of cupric citrate, 1-5 parts by weight of emulsifier, 3-6 parts by weight of coemulsifier, 7-20 parts by weight of excipient and 10-20 parts by weight of liquid glyceride.

Chewable tablet

The freeze-dried powder composition of the invention can be combined with various auxiliary materials to prepare chewable tablets. The chewable tablet is prepared by tabletting the following raw materials: 30 to 50 weight percent of the freeze-dried powder composition, 1 to 35 weight percent of xylitol, 1 to 35 weight percent of maltitol, 1 to 10 weight percent of maltodextrin, 1 to 15 weight percent of microcrystalline cellulose, 1 to 5 weight percent of polyvinylpyrrolidone and 0.1 to 0.5 weight percent of magnesium stearate, wherein the total amount is 100 weight percent.

The process for preparing the chewable tablet comprises the following steps:

Step 1, material taking: taking out 30-50 wt% of freeze-dried powder composition, 1-35 wt% of xylitol, 1-35 wt% of maltitol, 1-10 wt% of maltodextrin, 1-15 wt% of microcrystalline cellulose, 1-5 wt% of polyvinylpyrrolidone and 0.1-0.5 wt% of magnesium stearate according to the total amount of raw materials per 100 parts by weight to obtain the feeding amount;

Step 2, preparing mixed powder: sequentially adding the freeze-dried powder composition, xylitol, maltitol, maltodextrin, microcrystalline cellulose, polyvinylpyrrolidone and magnesium stearate into a mixer according to the weight percentage, uniformly mixing and stirring, and discharging to prepare mixed powder for later use;

Step 3, sieving: drying the mixed powder obtained in the step 2, and sieving;

step 4, tabletting and forming: and (3) adding the mixed powder dried and sieved in the step (3) into a tablet press to prepare chewable tablets.

In a preferred embodiment, in step 2, the mixer is a V-type mixer, and the mixing time of the mixer is 40-50 minutes.

Further, the method also comprises the following steps: step5, packaging, checking and warehousing, wherein the packaging comprises the following steps: and (3) inner packaging: bottling the tablet, 60 tablets/bottle; and an outer package: labeling and boxing.

The chewable tablet has the health-care effects of relieving visual fatigue and improving vision; the freeze-dried powder composition is prepared into the tablet, and the area of the tablet contacted with air is small after compression, so that the stability of the product is improved, and the quality of the product is effectively ensured. In addition, the dosage form of the invention is defined as a chewable tablet in the tablet, and the chewable tablet is prepared according to the taste and eating habit of the proper crowd, so that the crowd can accept the chewable tablet more easily. In addition, the tablet of the invention is convenient for transportation and storage, and improves the quality stability of health care food.

In particular, compared with the prior art that components such as She Huangsuan, blueberry powder, vitamin C, vitamin E and the like are directly tabletted, the freeze-dried powder composition can prevent oxidation of the unstable active components in the tableting process, improve stability, and simultaneously the chewable tablet prepared from the freeze-dried powder composition can improve in vivo absorbability and in vivo bioavailability.

Examples of the invention

PREPARATION EXAMPLE 1 preparation of vitamin E-lutein monosuccinate

56.9G of lutein (0.1 mol, from Sigma-Aldrich), 5.31g of natural vitamin E succinic monoester with purity of 100% (0.01 mol, from Sigma-Aldrich) and 3.28g of toluene sulfonic acid catalyst (from Meck company) were weighed into a four-necked flask, and the four-necked flask was purged with nitrogen, reacted at 160℃for 3 hours, cooled to room temperature after the completion of the reaction, and the purging was stopped. 200ml of ethyl acetate was added to a four-necked flask, the mixture was transferred to a separating funnel after stirring uniformly, washed three times with saturated saline (100 ml 3), the organic phase was collected, dried over anhydrous sodium sulfate and the solvent was evaporated to give vitamin E-lutein monosuccinate in 80.2% yield.

Authentication

IR measurement, scanning on NEXUS670 Fourier transform infrared spectrometer, taking KBr sheet as blank adjustment baseline, measuring infrared spectrogram of vitamin E-lutein monosuccinate KBr sheet, scanning range: 4000-40cm ^-1.

IR results-1860 cm ^-1 (ester C=O stretching vibration), 1777 and 1755cm ^-1 (C-C (=O) -O stretching vibration), 1712cm ^-1 (C=O stretching vibration), 1260cm ^-1 (O-C-C stretching vibration), 3490cm ^-1 (-OH asymmetric stretching vibration), 3280-3100cm ^-1 (-OH symmetric stretching vibration)

Nuclear magnetic measurement ¹ H-NMR-20 mg of the vitamin E-lutein monosuccinate powder obtained above was dissolved with CDCl ₃ at 25℃and ¹ H-NMR was performed on a bruker Advance DRX 500 nuclear magnetic resonance spectrometer (500 MHz). Tetramethylsilane is used as an internal standard.

¹H-NMR(500MHz,CDCl₃)：

δH 6.64(4H,m,H15,H15',H12,H12'),6.39(2H,m,H11,H11'),6.28(2H,m,H7,H8),6.15(5H,m,H10,H10',H14,H14',H8'),5.47(3H,m,H4',H7',H3'),5.11(1H,m,H3),2.80-3.22(m,H19),2.69(m,H19'),2.61-2.80(m,H20,H21),1.90-2.10(m,H22,H23),1.74-1.78(m,H25,H25'),1.48-1.67(m,H26,H27),1.17-1.48(m,H28,H28'),0.80-1.28(m,H30,H29)

Preparation example 2-preparation of lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt shown in formula I

Step 1, sequentially adding 20g of succinic anhydride, 150ml of N, N-Dimethylformamide (DMF) and 150ml of Tetrahydrofuran (THF) mixed solvent, 25g of vitamin E-lutein monosuccinate prepared by the method and 4g of 4-Dimethylaminopyridine (DMAP) into a clean reaction bottle, heating to 40 ℃ in a water bath, magnetically stirring until the solution is clear, and stirring and reacting for 3 hours at 50 ℃ to obtain a reaction solution;

Step 2, adding 100ml of acetone into the reaction liquid obtained in the step 1, stirring uniformly to obtain a mixed liquid, cooling the temperature of the mixed liquid to below 5 ℃, then adding purified water with the weight being 50 times of that of succinic anhydride obtained in the step 1 into the mixed liquid, crystallizing for 3 hours under the stirring condition of 0-5 ℃, filtering, and drying the obtained crystal at 60 ℃ to constant weight to obtain lutein succinic acid-tocopherol monoester-succinic acid monoester with the purity of 80.4% and the yield of 60%;

step 3, dissolving 15g of sodium bicarbonate into 300ml of water and uniformly mixing; adding 20g of lutein succinic acid-tocopherol monoester-succinic acid monoester obtained in the step 2 into sodium bicarbonate solution in two batches at 15-25 ℃ for uniform mixing; 100ml of acetone is added in two batches (each batch is 50ml, and the interval between the two batches is 30 minutes), and after the addition of the acetone is completed, the reaction is carried out for 3 hours at 15-25 ℃; after the reaction, the reaction solution was added into 3L of ice acetone at-20℃to precipitate a product, which was filtered to obtain a white solid, and further dried under vacuum at 40℃for 10 hours to obtain 29g of lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt. The detection is carried out: the yield is 83% and the purity is higher than 70%.

Example 1

S1-placing chopped chocolate (1.5 parts by weight relative to 100 parts by weight of the lyophilized powder composition) in a container of water which has been dried, then placing the container in hot water at 60℃and adding glyceryl caprylate (85.54 parts by weight) for stirring and filtering to obtain a filtered chocolate dispersion;

s2-taking 2.5 parts by weight of hydrogenated lecithin, 3 parts by weight of polyethylene glycol-400, 0.2 part by weight of zinc oxide and 0.06 part by weight of cupric citrate based on 100 parts by weight of the freeze-dried powder composition, adding the mixture into a filtered chocolate dispersion liquid, stirring and mixing the mixture uniformly for 40 minutes, placing the mixture into a water bath kettle for 30 minutes after stirring uniformly, and carrying out heat treatment at 50 ℃ to obtain a first dispersion liquid;

S3-cooling the first dispersion to room temperature, adding lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt (0.2 parts by weight), sodium ascorbate (2 parts by weight), mannitol and maltose (5 parts by weight total) obtained in preparation example 2, and stirring uniformly to obtain a second dispersion,

S4, placing the second dispersion liquid in a vacuum freeze dryer for vacuum freeze drying for 2 hours, wherein the vacuum pressure is 150Pa, and the temperature is-20 ℃ to obtain a block;

S5-ball milling is carried out on the block obtained in the step S4 by adopting a ball mill at a rotating speed of 20rpm, and then the powder obtained after ball milling is sent into a sieving machine for sieving, so that the freeze-dried powder composition is obtained.

Example 2

S1-placing chopped chocolate (5 parts by weight relative to 100 parts by weight of the lyophilized powder composition) in a container of water which has been wiped, then placing the container in hot water at 60 ℃, adding caprylic capric glyceride (67.2 parts by weight), stirring, and filtering to obtain a filtered chocolate dispersion;

S2-taking 5 parts by weight of hydrogenated lecithin, 3 parts by weight of polyethylene glycol-400, 0.9 part by weight of zinc oxide and 0.4 part by weight of cupric citrate based on 100 parts by weight of the freeze-dried powder composition, adding the mixture into a filtered chocolate dispersion liquid, stirring and mixing the mixture uniformly for 40 minutes, placing the mixture into a water bath kettle for 30 minutes after stirring uniformly, and carrying out heat treatment at 50 ℃ to obtain a first dispersion liquid;

S3-cooling the first dispersion to room temperature, adding lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt (0.5 weight parts), sodium ascorbate (5 weight parts), mannitol and maltose (total 13 weight parts) obtained in preparation example 2, and stirring uniformly to obtain a second dispersion,

Example 3

S3-cooling the first dispersion to room temperature, adding lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt (0.5 weight parts), blueberry powder (5 weight parts), sodium ascorbate (1 weight part), mannitol and maltose (total 12 weight parts) obtained in preparation example 2, and stirring uniformly to obtain a second dispersion,

Example 4

S1-placing chopped chocolate (5 parts by weight relative to 100 parts by weight of the lyophilized powder composition) in a container of water which has been wiped, then placing the container in hot water at 60 ℃, adding tricaprin (66.0 parts by weight), stirring, and filtering to obtain a filtered chocolate dispersion;

s2-taking 5 parts by weight of hydrogenated lecithin, 3 parts by weight of polyethylene glycol-400, 0.9 part by weight of zinc oxide and 0.4 part by weight of cupric citrate based on 100 parts by weight of the freeze-dried powder composition, adding the mixture into a filtered chocolate dispersion liquid, stirring and uniformly mixing the mixture for 110 minutes, placing the mixture in a water bath kettle for 40 minutes after uniform stirring, and carrying out heat treatment at 70 ℃ to obtain a first dispersion liquid;

S4, placing the second dispersion liquid in a vacuum freeze dryer for vacuum freeze drying for 3 hours, wherein the vacuum pressure is 200Pa, and the temperature is-20 ℃ to obtain a block;

s5-ball milling the block obtained in the step S4 by adopting a ball mill at a rotating speed of 50rpm, and then conveying the ball-milled powder into a sieving machine for sieving, thereby obtaining the freeze-dried powder composition.

Comparative example 1

S3-cooling the first dispersion to room temperature, adding natural vitamin E (0.2 weight part), lutein (0.2 weight part), sodium ascorbate (3 weight part), mannitol and maltose (total 5 weight parts) and uniformly stirring to obtain a second dispersion,

Comparative example 2

1.5 Parts by weight of chopped chocolate, 2.5 parts by weight of hydrogenated lecithin, 3 parts by weight of polyethylene glycol-400, 0.2 parts by weight of zinc oxide, 0.06 parts by weight of cupric citrate, natural vitamin E (0.2 parts by weight), lutein (0.2 parts by weight), sodium ascorbate (3 parts by weight), mannitol and maltose (total 5 parts by weight) and glyceryl caprylate (85.54 parts by weight) were uniformly stirred in a vacuum ball mill, and the resultant mixture was vacuum freeze-dried in a vacuum freeze-dryer for 2 hours at a vacuum pressure of 150Pa and a temperature of-20℃to obtain a cake. The obtained cake was ball-milled by a ball mill at 20rpm, and then the powder after ball milling was fed into a sieving machine to be sieved, thereby obtaining a lyophilized powder composition.

Comparative example 3

1.5 Parts by weight of chopped chocolate, 2.5 parts by weight of hydrogenated lecithin, 3 parts by weight of polyethylene glycol-400, 0.2 parts by weight of zinc oxide, 0.06 parts by weight of cupric citrate, natural vitamin E (0.2 parts by weight), lutein (0.2 parts by weight), sodium ascorbate (3 parts by weight), mannitol and maltose (total 90.54 parts by weight) were uniformly stirred in a vacuum ball mill, and the resultant mixture was vacuum freeze-dried in a vacuum freeze-dryer for 2 hours under a vacuum pressure of 150Pa at a temperature of-20℃to obtain a cake. The obtained cake was ball-milled by a ball mill at 20rpm, and then the powder after ball milling was fed into a sieving machine to be sieved, thereby obtaining a lyophilized powder composition.

Comparative example 4

S1-taking 5 parts by weight of hydrogenated lecithin, 3 parts by weight of polyethylene glycol-400, 0.9 part by weight of zinc oxide and 0.4 part by weight of cupric citrate to be added into 72.5 parts by weight of glyceryl caprylate, adding into a mixer, stirring and mixing for 40 minutes, placing into a water bath kettle for 30 minutes after stirring uniformly, and performing heat treatment at 50 ℃ to obtain a first dispersion;

S3-cooling the first dispersion to room temperature, adding lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt (0.2 parts by weight), sodium ascorbate (2 parts by weight), mannitol and maltose (16 parts by weight total) obtained in preparation example 2, and stirring uniformly to obtain a second dispersion,

Testing

Storage stability

Temperature stability

The samples of examples 1 to 4 and comparative examples 1 to 3 were each stored at 45℃under a light-shielding seal, and then the retention of the target components (i.e., lutein and sodium ascorbate) in the samples was measured on days 1, 25 and 40, respectively.

Retention% = (content of target component remaining/content of target component on initial day 0) ×100%

Light stability

The samples of examples 1 to 4 and comparative examples 1 to 3 were each kept under natural light for 1 day, 25 days and 40 days at room temperature, respectively, and then the retention of the target components (i.e., lutein, vitamin E and sodium ascorbate) in the samples was measured.

Retention = (content of target ingredient remaining/content of target ingredient of initial first day) ×100

Method for testing lutein and sodium ascorbate

The content of lutein, vitamin E and sodium ascorbate was detected using an Agilent high performance liquid chromatography system (Agilent corporation) comprising a binary gradient pump, a manual sample injector, a variable UV detector and a chromatographic column.

Chromatographic conditions for detecting lutein: the column was YMC Carotenoid C (4.6 mm x 250mm, inner diameter 5 microns); mobile phase: 0.05% acetic acid in methanol; flow rate: 1.2ml/min; column temperature: 25 ℃; sample injection amount: 10 microliters; detection wavelength: 450nm

Chromatographic conditions for detecting sodium ascorbate (vitamin C): the column was Shim-pack C30 (4.6 mm x 150mm, inner diameter 5 microns); mobile phase: methanol/potassium dihydrogen phosphate buffer (75/25); flow rate: 1.0ml/min; column temperature: 25 ℃; sample injection amount: 30 microliters; detection wavelength: 266nm

The content of the target component is respectively referred to an external standard method, a regression equation is obtained by using a standard solution, a concentration range with good linear relation of the target component is obtained, and then the content of each target component is calculated according to the regression equation.

Tables 1-2 show the results of the assays for vitamin C and lutein, respectively.

TABLE 1

/>

TABLE 2

/>

The results of tables 1 and 2 above show that examples 1 to 5 of the present invention improve the temperature stability and the light stability of vitamin C and lutein as compared to comparative examples 1 to 3. Since vitamin E is linked to lutein via succinate, it is also expected to improve vitamin E stability. In particular, example 3 has the best effect in improving storage stability, probably because lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt has carboxylate anionic group at one end, so it can form complex with the cation of blueberry phyllotoxin in blueberry powder, further improving the stability of active ingredient.

Mouse plasma concentration determination

1. Preparation of gastric lavage liquid

Samples of examples 1-4 and comparative examples 1-4 were added to a mixed solution containing 90 wt% physiological saline and 10 wt% corn oil, followed by 0.1 wt% pig bile salt, and sonicated to promote cell disruption. Finally, the emulsion with the vitamin E equivalent concentration of 10mg/ml is used for the stomach irrigation of SD rats.

2. Animal experiment

10 Healthy SD rats weighing 18-19kg were acclimatized for one week under exactly the same environmental and dietary conditions. 1 as reference example 1, no gastric lavage was performed, and 8 emulsions prepared by filling samples of examples 1 to 4 and comparative examples 1 to 4, respectively. 1 emulsion (reference example 2) obtained by the above method was filled with a commercially available multivitamin chewable tablet (containing 15mg of vitamin E and 100mg of vitamin C), rats were sacrificed after one week of continuous stomach filling, and whole blood was left, and plasma was separated. The plasma vitamin E concentration of each rat was determined according to the procedure described in the specification using the ELISA vitamin E assay kit from Brilliant Biotechnology. Plasma vitamin C concentrations of each rat were determined according to the procedure described in the specification using ELISA Vitamin C (VC) assay kit from Shenzhen subfamily Biotech. The relative plasma concentration values of examples 1-4, comparative examples 1-4 and reference example 2, i.e. relative plasma concentration values= (vitamin C or vitamin E plasma concentration of each mouse after one week of continuous gavage-vitamin C or vitamin E plasma concentration of the mouse of reference example 1)/vitamin C or vitamin E plasma concentration of the mouse of reference example 1 were calculated as 100%, respectively. The calculation results are shown in tables 3 and 4.

TABLE 3 Table 3

TABLE 4 Table 4

Sample of	Relative plasma concentration value of vitamin C (%)
		Example 1	165％
Example 2	159％
		Example 3	179％
Example 4	161％
		Comparative example 1	139％
Comparative example 2	129％
		Comparative example 3	128％
Comparative example 4	155％
		Reference example 1	100％
Reference example 2	121％

The test results in tables 3 and 4 show that the powder compositions of examples 1-4 of the present invention have significantly higher plasma concentrations than reference examples 1-2 and comparative examples 1-4, indicating that they have improved bioavailability. Consistent with the results of tables 1-2, example 3 showed the best enhancement of the plasma concentrations of vitamin C and vitamin E, indicating that the complex formed by the lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt and the cation of blueberry phyllotoxin in blueberry powder can further enhance the in vivo absorption and bioavailability of the active ingredients such as vitamin C and vitamin E.

Vision protection effect test

1. Arrangement of gastric lavage emulsion

Samples of examples 1-4 and comparative examples 1-4 were added to a mixed solution containing 90 wt% physiological saline and 10 wt% corn oil, followed by 0.1 wt% pig bile salt, and sonicated to promote cell disruption. Finally, the emulsion with the vitamin E equivalent concentration of 10mg/ml is used for gastric lavage.

Construction and testing of a model of C57BL6 mouse progressive deprivation myopia

2.1 Measuring diopters before molding: the new injection for quick sleep is injected into the guinea pig at the age of 3 weeks for sedation, the cycloartester hydrochloride eye drops are added dropwise once for 5 minutes for 4 times, the mydriasis condition of the animal is checked, and after the mydriasis of the animal is finished, the diopter of the animal is checked by a band-shaped photo-detector.

2.2 Anesthesia: hair around the eyes was cut after the animals were anesthetized.

2.3 Wearing glasses: the-10D aspheric hard coated resin lens was placed in a plastic ring which was sutured to the animal's orbit with a medical instrument mousse.

Checking whether the lens falls off or not: after the eyes of the animal wear the glasses, the animal is naturally awake, the animal wears the glasses for 3 weeks, the falling-off condition of the glasses is checked every morning and evening, and the postoperative care is immediately re-worn after the falling-off condition is found out

After the detection and modeling were successful, the gastric emulsions were infused separately, and the changes in diopter and ocular axis length of each group were measured after one month of continuous gastric infusion.

Detecting diopter: within a proper working distance (0.5 m), a strip-shaped optical inspection lens is used for keeping three holes and one line for diopter detection, forward and backward movement light bands are searched, and then positive and negative refraction sheets with different degrees are added and subtracted for digestion and neutralization, so that the final inspection refraction degree is obtained;

The test result is the change in diopter (-D) of the shift of the normal mouse eye toward myopia direction

Eye axis measurement: each group of rats was sacrificed and the eyeballs were placed on sterile gauze moistened with physiological saline, and the vernier caliper was used for in vitro ocular axis measurement, and repeated three times. The test result is an increased change in ocular axis length (+)' over normal mouse eyes.

The test results are shown in Table 5.

TABLE 5

The results in table 5 show that mice' eyesight is significantly improved or enhanced and an increase in ocular axis length is significantly inhibited after one month of gastric lavage using the emulsions of the compositions of examples 1-4 of the present invention. Example 3 most clearly improved vision, probably due to the increased bioavailability. Furthermore, the results of comparative example 4 show that the addition of chocolate increases the protective effect on vision and the inhibition of the increase in the length of the eye axis.

The above-described embodiment is only a preferred embodiment of the present invention, and is not limited in any way, and other modifications are possible without exceeding the technical solutions described in the claims. It is to be understood that the above embodiments are merely illustrative of the exemplary embodiments employed to illustrate the principles of the present disclosure, however, the present disclosure is not limited thereto. Various modifications and improvements may be made by those skilled in the art without departing from the spirit and substance of the disclosure, and are also considered to be within the scope of the disclosure.

Claims

1. A freeze-dried powder composition for eye protection and health care is characterized in that the freeze-dried powder composition is prepared from a dispersion liquid through freeze drying, wherein the dispersion liquid comprises lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt represented by a formula I, chocolate, vitamin C, zinc oxide, cupric citrate, emulsifying agent, auxiliary emulsifying agent, excipient and liquid glyceride,

2. The lyophilized powder composition according to claim 1 or 2, wherein the vitamin C is ascorbic acid or sodium ascorbate, and the lyophilized powder composition comprises the following raw material components in proportion: lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt 0.1-0.5 weight parts, chocolate powder 1-5 weight parts, vitamin C1-5 weight parts, zinc oxide 0.1-0.9 weight parts, cupric citrate 0.05-0.5 weight parts, emulsifying agent 1-5 weight parts, co-emulsifying agent 3-15 weight parts, excipient 5-15 weight parts, and liquid glyceride 65-86 weight parts.

3. The lyophilized powder composition of claim 2, wherein the raw material components of the lyophilized powder composition further comprise 5-15 parts by weight of blueberry powder, and the blueberry powder contains 20 to 40% by weight of blueberry anthocyanin.

4. A lyophilized powder composition according to any one of claims 1 to 3, characterized in that the emulsifier is selected from at least one of sorbitan sesquioleate, polysorbate, hydrogenated lecithin, hydrogenated castor oil polyoxyethylene ether-40, vitamin E polyethylene glycol succinate, span-85 and tween-20;

5. The lyophilized powder composition according to any one of claims 1 to 4, wherein the liquid glyceride is selected from at least one of glyceryl triacetate, glyceryl tricaprate and glyceryl caprylate.

6. A lyophilized powder composition as claimed in any one of claims 1 to 4, wherein the water content of the dispersion is controlled to be less than 0.5% by weight.

7. A method of preparing a lyophilized powder composition for eye care, comprising the steps of:

8. The method of preparing a lyophilized powder composition for eye protection according to claim 7, wherein step S3 further comprises adding blueberry powder to the first dispersion, and the blueberry powder contains 20 to 40 wt% blueberry anthocyanin.

9. The method for preparing a freeze-dried powder composition for eye protection and health care according to claim 7, wherein the vitamin C is ascorbic acid or sodium ascorbate, and the raw material components of the freeze-dried powder composition are as follows: lutein succinic acid-tocopherol monoester-succinic acid monoester sodium salt 0.1-0.5 weight parts, chocolate powder 1-5 weight parts, vitamin C1-5 weight parts, zinc oxide 0.1-0.9 weight parts, cupric citrate 0.05-0.5 weight parts, emulsifying agent 1-5 weight parts, co-emulsifying agent 3-15 weight parts, excipient 5-15 weight parts, and liquid glyceride 65-86 weight parts.

10. A chewable tablet for eye care and health care, characterized in that the chewable tablet is prepared by tabletting the following raw materials: the lyophilized powder composition for eye protection according to any one of claims 1 to 6, which comprises 30 to 50 wt%, xylitol 1 to 35 wt%, maltitol 1 to 35 wt%, maltodextrin 1 to 10 wt%, microcrystalline cellulose 1 to 15 wt%, polyvinylpyrrolidone 1 to 5wt%, magnesium stearate 0.1 to 0.5 wt%, and the total amount is 100 wt%.